|
|
 |
|
Viewing report
|
|
|
|
New Strategies in Pharmaceutical Academic-Industry Collaborations
Decision Resources, Inc., June 2009, Pages: 23
Major pharmaceutical companies are showing increased interest in directly sponsoring academic research to access innovation and fill dwindling pipelines. Recent agreements involve higher levels of collaboration and funding, are broader in scope, and focus on more-basic research than previously. This increased collaboration among scientists performing basic research, clinical researchers, and drug developers will accelerate the shift to translational medicine and has the potential to yield great benefits to patients and society.
Questions Answered in This Report
- Pharmaceutical companies have recently formed numerous collaborations with large research institutions. What factors are driving this interest? What are the key features of recent collaborative agreements? How does each organization benefit from these arrangements?
- The environment of academic technology transfer to industry is changing. What impact has the Bayh-Dole Act had on technology transfer? How do academic institutions manage academic industry relationships? Which institutions are leading in innovation and commercialization of
technology?
- Drug developers are experimenting with different approaches to academic-industry relations. Which key collaborations illustrate these new approaches? What strategic interests of the pharmaceutical industry do these agreements serve? How will universities and companies measure success?
- Relationships between academia and industry present special challenges. How do the missions and goals of academia and industry differ? What conflicts can arise with respect to industry funding of academic researchers? How can institutions and companies manage these differences?
Scope
- Factors in academic-industry collaborations: historical relationships, dwindling pharmaceutical pipelines, diminishing federal funding for academia.
- Technology transfer: impact of Bayh-Dole, tech transfer offices, inventions and innovation, challenges in academic-industry relationships.
- New approaches in academic-industry relationships: close-collaboration, broad-scope, early-stage research.
- Translational medicine: theme of collaborations, goals, motivations.
- Drug discovery centers: academic centers for dug discovery, industry discovery centers, pharmaceutical incubators.
- Notable collaborators: AstraZeneca, Centocor, GlaxoSmithKline, Janssen Pharmaceutica, Merck, Novartis, Pfizer; Columbia University Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Immune Disease Institute, MIT, University of California, San Francisco, University of Michigan, Vanderbilt University, Washington University.
Customers who bought this item also bought
Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural Factors, Intellectual Property Considerations, Case Studies, and Future Trends
Licensing Opportunities: Neurology
Developments in Early-Stage Toxicity Prediction
Dealmaking and Financing: Buying in Innovation
The Neurotechnology Industry 2011 Report
The Central Nervous Systems Market 2010 Report
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Narrowing the Innovation Gap with Fragment-Based Drug Discovery and Design
Navigating the Drug Discovery Landscape: A Strategic Overview of Pharmaceutical R&D
|
|
|
|
